Alessandra Tedeschi, MD, discusses data from a subgroup analysis of the phase 3 SEQUOIA trial in CLL/SLL.
Back
Dissecting Long-Term Data for Zanubrutinib in Older Treatment-Naive CLL
Alessandra Tedeschi, MD, and colleagues presented data from a subgroup analysis of older patients with CLL treated with zanubrutinib during the SEQUOIA trial.
Dissecting Long-Term Data for Zanubrutinib in Older Treatment-Naive CLL
Episodes
All
All
Zanubrutinib yielded sustained progression-free survival and a tolerable safety profile in older patients with CLL/SLL treated in the SEQUOIA trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
FDA Flashback: Breast Cancer Decisions and News From July 2026
3
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
4
Dr Wong on the FDA Approval of Vusolimogene Oderparepvec-wtpg Plus Nivolumab in Melanoma
5